



June 14, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Ennaid Therapeutics partners exclusively with Strides to manufacture
life-saving oral Covid-19 Tablet”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

A handwritten signature in blue ink that reads 'Manjula R.'.

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com



ENNAID THERAPEUTICS PARTNERS EXCLUSIVELY WITH STRIDES TO MANUFACTURE LIFE-SAVING ORAL COVID-19 TABLET

- **Partnership for an oral repurposed medication to treat mild, moderate and asymptomatic cases of COVID-19**
- **Strides to be the exclusive manufacturing partner for the product globally**

GEORGIA, US and BENGALURU, INDIA – June 14, 2021 – Strides Pharma Science Limited today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID-19.

Ennaid's partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID-19 using artificial intelligence drug discovery platforms. Initial tests show antiviral activity effective against SARS CoV-2, the virus that causes COVID-19, by inhibiting 90% of the virus' replication in vitro studies. These results are so compelling that Ennaid is ready to seek emergency authorization from the FDA in the United States as well an approval for compassionate use in India. Strides will be the exclusive manufacturing partner to Ennaid for the product.

Ennaid's CEO, Darnisha Harrison, commented on the impact of the epidemic and partnership with Strides: "The magnitude of human loss in India due to COVID-19 compelled Ennaid India Private Limited to partner with Strides Pharma extending critical resources to aid its government. We are honored to join forces with an India-based company to bring hope and healing at a time when it's critically needed. Since the drug was previously approved by the FDA for other indication, it has already been proven safe in humans. What we have will not only bring much needed relief to India but to patients around the world. With more than 30 million people infected with COVID-19 in America and over 100 million in the world, a drug that treats mild to moderate symptoms and helps block replication of the virus is a top priority"

Dr R Ananthanarayanan, Managing Director and Group CEO, Strides, stated: "We are pleased to partner with Ennaid as an exclusive manufacturer of its oral repurposed medication to treat mild, moderate and asymptomatic cases of COVID-19. At Strides we are committed in our fight against COVID-19 and are working on creating a portfolio of products to aid COVID treatment and supportive care. Partnership with Ennaid is part of our initiative to provide quality and affordable treatment to the global patient pool impacted by COVID-19."

About Ennaid

Ennaid is a global biopharmaceutical company based in the United States, with subsidiaries in Australia, the United Kingdom, and India. Ennaid is developing a robust pipeline of therapeutics to treat COVID-19 and other deadly, infectious diseases affecting humans and animals worldwide using artificial intelligence drug discovery platforms. The company's immediate focus is developing an antiviral treatment for COVID-19, but also has a rich mosquito-borne disease pipeline of patented, new therapeutics targeting dengue virus, Zika virus, West Nile virus, as well as a patented, repurposed drug that may treat advanced-stage colorectal cancer.

Ennaid has two promising digital health products under development. One is a software-based diagnostic that diagnosis and measures traumatic brain injuries, such as concussions; the other is a clinical trial reporting software with telemedicine features. The Five Pillars of Ennaid are coronavirus, infectious disease, oncology, digital health and animal health. For more details, please visit <https://ennaidthera.com>

About UCAM

Strategically located in Murcia, Spain, with a Campus of more than 16,000 students and around 1,000 professors, UCAM is expanding worldwide to make their main objectives a reality: to promote a high-quality university

education, with a representative presence in all continents. UCAM has a friendly and international environment in a privileged Mediterranean framework that collaborates with universities from all corners of the planet, at every educational level: research, students and professors exchange and create international undergraduate and master's programs in all specialties. The computational drug design group is formed by the scientists Horacio Pérez-Sánchez, José Pedro Cerón-Carrasco, Jorge Peña-García, Alfonso Pérez-Garrido and Antonio Jesús Banegas Luna.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Ennaid Contact: *Daniel Tenezo, Chief Communications Officer, daniel@ennaidthera.com*

Strides Contact: *Sandeep Baid, Investor Relations, Sandeep.baid@strides.com*